Full Press Release Details
Precigen Highlights Pipeline Updates to be Presented
42nd Annual J.P. Morgan Healthcare Conference
January 8, 2024 - Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing
in the development of innovative gene and cell therapies to improve the lives of patients, today released highlights of pipeline updates
to be presented at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024 at 5:15 PM PST in San Francisco, California.
AdenoVerse Immunotherapies
quarter of this year, we anticipate presenting Phase 2 pivotal study data for our lead asset, PRGN-2012, in recurrent respiratory papillomatosis,
RRP, and submitting the Company's first BLA under an accelerated approval pathway in the second half of this year. In anticipation
of a potential launch in 2025, we are actively preparing for commercial readiness. This is an exciting time for Precigen as we prepare
to transition from a clinical to commercial stage biotechnology company. I am incredibly proud of the Precigen team for achieving the
first breakthrough therapy designation and accelerated approval pathway so rapidly for an RRP treatment and for the life-changing potential
that PRGN-2012 has for RRP patients," said Helen Sabzevari, PhD, President and CEO of Precigen.
to advance our UltraCAR-T clinical programs and remain enthusiastic about the data we are seeing in our Phase 1b expansion studies. Precigen's
UltraCAR-T cell therapies are engineered to specifically address the limitations of conventional CAR-T therapies by improving in vivo
CAR-T expansion and persistence, adding a safety/kill switch to reduce the risk of toxicity and malignancy, utilizing a non-viral
design to reduce the risk of malignant transformation associated with lentivirus and retrovirus vectors, eliminating long turnaround
times for manufacturing and reducing the high cost of treatment," adds Sabzevari. "We look forward to sharing new results
for these assets during the planned presentations for our PRGN-3006 and PRGN-3007 UltraCAR-T programs in 2024. In addition to ongoing
clinical trials, we are excited by the preclinical data for a new and differentiated CD19 targeted UltraCAR-T, which has best-in-class
potential for this validated target capitalizing on the unique advantages of the UltraCAR-T platform over conventional CAR-T."
42nd Annual J.P. Morgan Healthcare Conference presentation will be available on the Company website in the Events
& Presentations section following the presentation.
Medicine with Precision
PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies
using precision technology to target the most urgent and intractable diseases in our core therapeutic areas of immuno-oncology, autoimmune
disorders, and infectious diseases. Our technologies enable us to find innovative solutions for affordable biotherapeutics in a controlled
manner. Precigen operates as an innovation engine progressing a preclinical and clinical pipeline of well-differentiated therapies toward
LinkedIn or YouTube.
Precigen, UltraCAR-T,
UltraPorator, AdenoVerse and Advancing Medicine with Precision are trademarks of Precigen and/or its affiliates. Other names
may be trademarks of their respective owners.
Cautionary Statement Regarding Forward-Looking Statements
Some of the statements
made in this press release are forward-looking statements. These forward-looking statements are based upon the Company's current expectations
and projections about future events and generally relate to plans, objectives, and expectations for the development of the Company's
business, including the timing and progress of preclinical studies, clinical trials, discovery programs, product candidate approval and
commercialization and related milestones, the promise of the Company's portfolio of therapies, and in particular its CAR-T and AdenoVerse
therapies. Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are
reasonable, all forward-looking statements involve risks and uncertainties and actual future results may be materially different from
the plans, objectives and expectations expressed in this press release. The Company has no obligation to provide any updates to these
forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety
by this cautionary statement. For further information on potential risks and uncertainties, and other important factors, any of which
could cause the Company's actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk
Factors" in the Company's most recent Annual Report on Form 10-K and subsequent reports filed with the Securities and Exchange
Vice President, Investor
Tel: +1 (301) 556-9850